OakChart

INmune Bio Inc

INMBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 10:04 AM ET

1.13+0.03 (2.73%)
2026-11-11 16:08 CET
Market cap
34.05 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-16.67 USD m
Free cash flow, TTM
-13.49 USD m
EPS diluted, TTM
-0.62
P/E
-
Compare

Price

INMB against its 20, 50 and 200-day averages
2050200beatmiss
1.001.502.002.506.2M12.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INMBclose 1.1320-day 1.4150-day 1.81200-day 1.621.13

56.5% under 2.60 on 8 Sep 2026. Last 15 sessions, 55.7% high to low

Profile

INMB
52-week range, 5% of the way up
1.062.60

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer's disease. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

Employees21
IPOFeb 04, 2019
Beta0.97
ATR, 14d0.12
Rel volume0.57
Short float9.63%
Insider own10.81%
Inst own14.56%

Snapshot

6 groups

Valuation

Index-
Market Cap34.98M
Enterprise Value19.86M
Income-16.67M
Sales0.00M
Book/sh0.65
Cash/sh0.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees21
IPOFeb 04, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.75
P/C2.14
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.41
Current Ratio6.41
Debt/Eq0.07
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.62
EPS next Y-0.77
EPS next Q-0.21
EPS this Y67.74%
EPS next Y-28.33%
EPS next 5Y25.15%
EPS past 3/5Y-6.80% -12.95%
Sales past 3/5Y-48.87% 35.58%
EPS Y/Y TTM71.08%
Sales Y/Y TTM-100.00%
EPS Q/Q30.24%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.-15.88% -

Ownership

Insider Own10.81%
Insider Trans0.00%
Inst Own14.56%
Inst Trans-5.12%
ROA-60.75%
ROE-76.71%
ROIC-89.65%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-19.84%
SMA50-37.64%
SMA200-30.18%
Trades-

Technical

Shs Outstand27.92M
Shs Float27.61M
Short Float9.63%
Short Ratio8.17
Short Interest2.66M
52W High2.60 -56.54%
52W Low1.06 6.60%
Volatility11.87% 9.08%
ATR (14)0.12
RSI (14)26.30
Beta0.97
Rel Volume0.57
Avg Volume325.42K
Volume25,920

Performance

Perf Week-15.04%
Perf Month-32.74%
Perf Quarter-45.67%
Perf Half Y-22.60%
Perf YTD-27.56%
Perf Year-25.17%
Perf 3Y-83.53%
Perf 5Y-92.27%
Perf 10Y-
Recom1.00
Target Price7.00
Prev Close1.10
Price1.13
Change %2.73%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Jul 01, 2025DowngradeBScotiabankSector Outperform → Sector Underperform$0.60-46.9%
Jul 01, 2025DowngradeBBTIG ResearchBuy → Neutral
Jan 28, 2025InitiatedRRodman & RenshawBuy$23+1,935.4%
Oct 21, 2024InitiatedAAlliance Global PartnersBuy$20+1,669.9%
Sep 27, 2024InitiatedRRaymond JamesOutperform$18+1,492.9%
Aug 22, 2024InitiatedBScotiabankSector Outperform$22+1,846.9%
Jun 01, 2023InitiatedRRobert W. BairdOutperform$16+1,315.9%
May 24, 2022DowngradeRB. Riley SecuritiesBuy → Neutral$14 → $7+519.5%
Jul 07, 2021ReiteratedMMaxim GroupBuy$32 → $42+3,616.8%
Apr 21, 2021InitiatedRB. Riley SecuritiesBuy$29+2,466.4%

Peers

Mkt cap
TickerCompanyMkt cap
ANVSAnnovis Bio Inc35.34M
CGTXCognition Therapeutics Inc64.66M
PMNProMIS Neurosciences Inc36.50M
ABOSAcumen Pharmaceuticals Inc16.42M
ACIUAC Immune SA230.01M
AVXLAnavex Life Sciences Corp103.36M
COYACoya Therapeutics Inc75.30M
BIVIBioVie Inc13.93M
ALECAlector Inc400.48M
ALZNAlzamend Neuro Inc6.85M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Juda ScottDirectorJul 02 '26Option Exercise1.4014,80120,72186,404Jul 07 07:01 AM
Lowdell Mark WilliamChief Scientific OfficerJul 02 '26Option Exercise1.407,21110,0951,518,017Jul 07 07:01 AM
Moss David JChief Executive OfficerJul 02 '26Option Exercise1.409,01412,6201,294,883Jul 07 07:00 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFMCU.S. Micro Cap Portfolio ETF Class Shares-
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • INmune Bio Narrows Its Loss, But Another Ebstrocel Timeline Slip And Rising Dilution Define The Quarter (Earnings Whispers) -11.65%
  • INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update (GlobeNewswire)
  • INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th (GlobeNewswire)
  • INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
  • Manufacturing Progress Gives INmune Bio a Clearer UK Filing Path for Ebstrocel (InvestorsHub)
  • Loading…
  • INmune Bio Advances Ebstrocel Toward Potential UK Approval in Mid-2027 (GlobeNewswire)
  • INmune Bio Establishes Global Commercialization Framework for Ebstrocel Through Strategic Agreement with Uniphar (GlobeNewswire)
  • QCi and INmune Bio partner to study XPro in Alzheimers (Pharmaceutical Technology)
  • INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro (FinanceWire)
  • INmune Bio to Attend the 2026 Maxim Growth Summit (GlobeNewswire)
  • INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board (GlobeNewswire)
  • INmune Bio to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
  • INmune Bio Advances Ebstrocel Toward European Marketing Authorization with EMA Regulatory Filings (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.170-0.147-0.1700.000.003
2026Q22026-08-06-0.050-0.207-0.0480.000.003
2026Q12026-05-07-0.200-0.245-0.2030.000.004
2025Q42026-03-30-0.198-0.270-0.1980.000.002
2025Q32025-10-30-0.240-0.318-0.2430.000.005
2025Q22025-08-07-1.050-0.384-1.0500.000.005
2025Q12025-05-08-0.430-0.471-0.4330.050.005
2024Q42025-03-27-0.400-0.548-0.4140.000.006
2024Q32024-10-31-0.600-0.507-0.5990.000.006
2024Q22024-08-01-0.500-0.630-0.5050.000.013
2024Q12024-05-09-0.610-0.535-0.6120.010.032
2023Q42024-03-28-0.470-0.427-0.4680.030.043
2023Q32023-11-01-0.480-0.393-0.4760.040.053
2023Q22023-08-07-0.360-0.397-0.3620.050.043
2023Q12023-05-03-0.360-0.020-0.3640.04-1
2022Q42023-03-02-0.320-0.485-0.3260.090.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.750-0.793-0.7470.000.00
2020FY-1.010-1.090-1.0090.010.00
2021FY-1.880-1.914-1.8810.180.01
2022FY-1.520-1.660-1.5230.370.20
2023FY-1.670-1.650-1.6690.160.14
2024FY-2.110-2.259-2.1100.010.01
2025FY-1.860-1.930-1.8600.050.10
2026FY--0.550--0.00
2027FY--0.770--9.54
2028FY--0.780--23.91
2029FY-0.780--96.56
2030FY-1.920--168.59

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-062000.000.000.00
2026Q4S2026-11-052000.000.000.00
2026Q4S2026-08-072000.000.000.00
2026Q4S2026-05-082000.000.000.00
2026Q4S2026-03-312000.000.000.00
2026Q4S2026-02-111000.000.000.00
2026Q4R2026-11-06200-0.22-0.23-0.21
2026Q4R2026-11-05200-0.22-0.23-0.21
2026Q4R2026-10-25200-0.22-0.23-0.21
2026Q4R2026-10-21201-0.22-0.23-0.21
2026Q4R2026-08-11211-0.22-0.23-0.21
2026Q4R2026-08-07210-0.22-0.23-0.20
2026Q4R2026-07-29200-0.25-0.29-0.20
2026Q4R2026-07-22201-0.25-0.29-0.20

Estimate history

EPS, annual-0.074-1.277-0.747-1.009-1.881-1.523-1.669-2.11-1.855-0.6188
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.599-0.414-0.433-1.05-0.243-0.198-0.203-0.048-0.17
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000.0110.1810.3740.1550.0140.050
Period201720182019202020212022202320242025TTM
Sales, quarterly000.05000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual11.2199.7410.77113.48117.84317.94617.95122.2826.58527.916
Period201720182019202020212022202320242025MRQ
Shares, quarterly22.17222.2822.9326.58526.58526.58526.58527.65427.916
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.050.010.150.370.180.010.000.00
Cost of Goods Sold Incl. D&A0.250.08-----0.000.00
Gross Profit-0.25-0.03-----0.000.00
Selling, General and Administrative Excl. Other17.5230.8442.6529.9026.3229.3312.247.7612.44
Research and Development8.3320.6633.1720.2717.0720.545.923.281.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-17.77-30.87-42.63-29.74-25.95-29.15-12.23-7.76-12.44
Interest Expense0.000.00----0.000.000.00
Unusual Expense0.0015.910.000.000.000.000.000.000.00
Net Income Before Taxes-16.67-45.93-42.08-30.01-27.30-30.34-12.10-7.68-12.44
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-16.67-45.93-42.08-30.01-27.30-30.34-12.10-7.68-12.44
Net Income From Continuing Operations-16.67-45.93-42.08-30.01-27.30-30.34-12.10-7.68-12.44
Net Income-16.67-45.93-42.08-30.01-27.30-30.34-12.10-7.68-12.44
EPS (Recurring)-0.60-1.41-2.11-1.67-1.52-1.88-1.01-0.75-1.28
EPS (Basic, Before Extraordinaries)-0.62-1.86-2.11-1.67-1.52-1.88-1.01-0.75-1.28
EPS (Diluted)-0.62-1.86-2.11-1.67-1.52-1.88-1.01-0.75-1.28
EBITDA-17.52-30.79-42.63-29.74-25.95-29.15-12.23-7.76-
Non-Operating Income (Expense)1.100.850.55-0.27-1.35-1.190.130.080.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.299.917.617,368.007.154.803.114.1010.00
Price To Sales Ratio-772.446,652.851,306.22303.90909.0118,911.86--
Gross Margin--68.00-------
Operating Margin--61,738.00-304,535.71-19,187.74-6,938.77-16,106.63-112,016.09--
Net Margin--91,866.00-300,585.71-19,360.00-7,299.20-16,762.43-110,838.76--
Shares Outstanding27.9226.5922.2817.9517.9517.8413.4810.779.74
Market Capitalization34.0534.05103.55202.92113.78182.00231.5762.6457.44

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.050.00
Cost of Goods Sold Incl. D&A0.070.070.050.060.030.00-0.00
Gross Profit-0.07-0.07-0.05-0.06-0.030.00-0.00
Selling, General and Administrative Excl. Other4.941.415.765.427.418.069.969.47
Research and Development3.16-0.803.642.334.895.807.647.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.01-1.48-5.81-5.47-7.43-8.06-9.90-9.47
Interest Expense0.000.000.000.000.000.00--
Unusual Expense0.000.000.000.00-0.6016.510.000.00
Net Income Before Taxes-4.72-1.27-5.41-5.26-6.47-24.46-9.74-9.22
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.72-1.27-5.41-5.26-6.47-24.46-9.74-9.22
Net Income From Continuing Operations-4.72-1.27-5.41-5.26-6.47-24.46-9.74-9.22
Net Income-4.72-1.27-5.41-5.26-6.47-24.46-9.74-9.22
EPS (Recurring)-0.17-0.05-0.20-0.20-0.26-0.55-0.43-0.41
EPS (Basic, Before Extraordinaries)-0.17-0.05-0.20-0.20-0.24-1.05-0.43-0.41
EPS (Diluted)-0.17-0.05-0.20-0.20-0.24-1.05-0.43-0.41
EBITDA-4.94-1.41-5.76-5.42-7.41-8.06-9.90-9.47
Non-Operating Income (Expense)0.290.200.410.210.360.110.170.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.121.361.503.322.981.532.081.76
Price To Sales Ratio---829.461,100.631,076.393,513.917,432.12
Operating Margin-------19,810.00-
Net Margin-------19,478.00-
Shares Outstanding27.9227.6526.5926.5926.5926.5922.9322.28
Market Capitalization34.0543.3330.0441.4755.0353.62207.68103.55

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments24.7520.9235.8552.1574.8121.977.000.191.37
Short Term Receivables4.541.412.448.465.501.800.650.650.33
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.590.331.654.062.290.220.120.020.20
Total Current Assets29.8922.6639.9464.6782.6123.997.760.851.90
Net Property, Plant & Equipment1.870.310.410.510.730.160.190.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.0016.5116.5116.5116.5116.5116.5116.5116.51
Other Assets0.590.080.130.100.100.000.000.000.00
Total Assets32.3539.5657.0081.8099.9440.6624.4717.3618.41
Short Term Debt Incl. Current Port. of LT Debt0.620.1410.045.090.070.030.010.000.00
Accounts Payable7.796.567.945.213.811.550.690.820.31
Other Current Liabilities0.000.520.490.620.470.19-0.000.000.00
Total Current Liabilities8.427.2218.4610.924.361.780.700.820.31
Long Term Debt0.410.240.4010.2215.160.130.160.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.550.200.000.000.000.00
Total Liabilities8.837.4618.8621.6919.721.900.860.820.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity23.5232.1038.1460.1080.2238.7523.6116.5418.10
Total Shareholders Equity23.5232.1038.1460.1080.2238.7523.6116.5418.10
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity23.5232.1038.1460.1080.2238.7523.6116.5418.10
Total Liabilities & Stockholders Equity32.3539.5657.0081.8099.9440.6624.4717.3618.41
Book Value Per Share0.881.442.123.354.502.872.191.701.61
Tangible Book Value Per Share0.880.701.202.433.571.650.660.000.14
Full-Time Employees21221710105432
Price to Book Ratio1.702.684.521.792.275.992.652.32-
Return on Assets-127.75-87.16-43.24-30.04-43.16-37.16-36.71-69.54-8.82
Return on Equity-165.16-119.83-61.09-38.91-51.00-38.80-38.25-71.82-9.26
Return on Invested Capital-191.91-130.12-77.87-38.82-31.81-31.12-32.30-75.21-4.59
Quick Ratio3.553.142.165.9218.9513.5011.091.036.13
Current Ratio3.553.142.165.9218.9513.5011.091.036.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-16.67-45.93-42.08-30.01-27.30-30.34-12.10-7.68-12.44
Depreciation0.250.08-------
Other Funds (Non Cash)7.2025.807.687.597.484.923.112.5510.00
Funds from Operations-9.21-20.05-34.40-22.42-19.82-25.42-8.99-5.12-2.44
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.70-2.531.0410.44-2.86-3.090.04-0.260.38
Cash from Operating Activities-12.91-22.58-33.36-11.98-22.69-28.50-8.94-5.38-2.06
Capital Expenditures-0.57-1.040.000.000.00-15.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.57-1.040.000.000.00-15.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.0727.5428.210.780.7381.4123.9012.210.90
Repurchase of Common Pref Stock0.000.000.000.000.000.00-1.010.000.00
Sale of Common Pref Stock2.0727.5428.210.780.7381.4124.9112.210.90
Proceedsfrom Stock Options1.050.000.000.000.031.1524.9112.210.90
Issuance or Reduction of Debt, Net0.000.00-10.00-5.000.0014.950.000.000.00
Change in Long Term Debt0.000.00-10.00-5.000.0014.950.000.000.00
Issuance of Long Term Debt0.000.000.000.000.0014.950.000.000.00
Reduction of Long Term Debt0.000.00-10.00-5.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.070.070.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities2.1427.6118.21-4.220.7396.3623.9012.210.90
Exchange Rate Effect-0.06-0.160.22-0.10-0.70-0.010.02-0.02-0.03
Net Change in Cash-11.403.83-14.93-16.30-22.6652.8414.976.81-1.18
Free Cash Flow-13.49-23.62-33.36-11.98-22.69-28.50-8.94-5.38-2.06
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments16.3318.4121.3624.7527.7333.37
Short Term Receivables1.734.770.774.542.462.15
Inventories0.000.000.000.000.000.00
Other Current Assets0.650.620.690.590.470.51
Total Current Assets18.7123.8022.8229.8930.6736.03
Net Property, Plant & Equipment2.272.512.311.871.941.08
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets---0.000.000.00
Other Assets0.530.540.680.590.750.57
Total Assets21.5127.6625.8232.3533.3637.68
Short Term Debt Incl. Current Port. of LT Debt0.690.810.700.620.460.22
Accounts Payable2.235.084.687.796.907.86
Other Current Liabilities-0.00-0.00-0.000.00-0.000.51
Total Current Liabilities2.925.895.398.427.368.59
Long Term Debt0.520.590.810.410.620.23
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.446.486.198.837.988.82
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18.0721.1819.6223.5225.3828.87
Total Shareholders Equity18.0721.1819.6223.5225.3828.87
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.0721.1819.6223.5225.3828.87
Total Liabilities & Stockholders Equity21.5127.6625.8232.3533.3637.68
Book Value Per Share0.650.770.740.880.951.09
Tangible Book Value Per Share0.650.770.740.880.951.09
Full-Time Employees---21--
Price to Book Ratio1.702.211.281.631.911.79
Return on Assets-60.75-56.37-130.78-127.75-115.83-123.16
Return on Equity-76.71-73.60-168.78-165.16-155.77-168.34
Return on Invested Capital-25.40-5.85-26.47-21.99-24.89-84.05
Quick Ratio6.414.044.243.554.174.20
Current Ratio6.414.044.243.554.174.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.72-1.27-5.41-5.26-6.47-24.46
Depreciation0.070.070.050.06--
Other Funds (Non Cash)1.121.361.413.322.3618.05
Funds from Operations-3.520.15-3.95-1.89-4.09-6.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.13-3.330.55-1.05-1.35-0.96
Cash from Operating Activities-3.39-3.17-3.40-2.94-5.44-7.38
Capital Expenditures0.00-0.430.00-0.14-0.19-0.71
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.430.00-0.14-0.19-0.71
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.330.750.00-0.000.0022.27
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.330.750.00-0.000.0022.27
Proceedsfrom Stock Options0.460.580.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.070.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.330.750.000.070.0022.27
Exchange Rate Effect-0.02-0.090.010.04-0.01-0.15
Net Change in Cash-2.08-2.95-3.39-2.98-5.6414.04
Free Cash Flow-3.39-3.60-3.40-3.09-5.63-8.08

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 14.00K 2025: 50.00K
United States2024: 14.00K 2025: 50.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.63%2.7M27.6M329.58K
2026-10-1511.66%2.9M24.8M356.11K
2026-09-3010.74%2.7M24.8M472.42K
2026-09-159.10%2.3M24.8M721.92K
2026-08-318.87%2.2M24.6M721.75K
2026-08-148.54%2.1M24.6M722.73K
2026-07-318.95%2.2M24.6M762.20K
2026-07-1510.11%2.4M23.6M745.41K
2026-06-3012.99%3.1M23.6M620.55K
2026-06-1515.53%3.7M23.6M394.06K
2026-05-2915.62%3.7M23.6M432.71K
2026-05-1515.42%3.6M23.6M476.28K
2026-04-3016.05%3.5M22.1M410.81K
2026-04-1515.27%3.4M22.1M432.58K
2026-03-3115.53%3.4M22.1M434.18K
2026-03-1314.76%3.3M22.1M409.11K
2026-02-2717.26%3.8M22.1M423.42K
2026-02-1317.97%4.0M22.1M397.88K
2026-01-3018.35%4.0M22.1M408.21K
2026-01-1517.66%3.9M22.1M407.41K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.000.750.0011.6400.000.000.893-0.0270.000
call2.000.000.050.053.23493.000.000.195-0.0080.000
call3.000.000.050.104.4739910.000.158-0.0100.000
call4.000.000.050.005.2620.000.000.143-0.0110.000
call5.000.000.050.005.8370.000.000.135-0.0120.000
put1.000.000.750.0015.0610.000.00-0.107-0.0270.000
put2.000.501.400.9010.4555.000.00-0.805-0.0090.000
put3.001.502.250.009.8740.000.00-0.842-0.0100.000
put4.002.303.300.0011.3770.000.00-0.858-0.0110.000
put5.003.404.400.0013.4220.000.00-0.866-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-27SEC
2026-10-29424B5SEC
2026-10-218-KCurrent report2026-10-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-233Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-163Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-148-KCurrent report2026-09-08SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-318-KCurrent report2026-07-31SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-018-KCurrent report2026-06-30SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-178-KCurrent report2026-06-16SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-04-29SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-16SEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-278-KCurrent report2026-02-27SEC
2026-02-238-KCurrent report2026-02-23SEC
2026-02-198-KCurrent report2026-02-19SEC
2026-02-138-KCurrent report2026-02-10SEC
2026-01-278-KCurrent report2026-01-27SEC
2025-12-238-KCurrent report2025-12-22SEC
2025-12-198-KCurrent report2025-12-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.66%
AQR CAPITAL MANAGEMENT LLC2.49%
BlackRock, Inc.1.17%
GEODE CAPITAL MANAGEMENT, LLC0.87%
RAYMOND JAMES FINANCIAL INC0.80%
GOLDMAN SACHS GROUP INC0.70%
MILLENNIUM MANAGEMENT LLC0.60%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.60%
JANE STREET GROUP, LLC0.50%
UBS Group AG0.40%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.84%
Fidelity Small Cap Index Fund0.80%
VANGUARD EXTENDED MARKET INDEX FUND0.74%
Fidelity Extended Market Index Fund0.61%
VANGUARD RUSSELL 2000 INDEX FUND0.43%
iShares Micro-Cap ETF0.31%
Schwab Small-Cap Index Fund0.19%
Fidelity Total Market Index Fund0.11%
Fidelity Series Total Market Index Fund0.10%
VANGUARD BALANCED INDEX FUND0.08%

OakChart. INMB. Cached 15 minutes.